- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 22.12.25 | Coherent Solutions closes strategic investment led by IceLake | 276 | Coherent Solutions, a global digital engineering firm, has announced the closing of the strategic investment from IceLake, a leading private equity investor specializing in partnering with high-growth... ► Artikel lesen | ||
| 22.12.25 | Bruker Corporation: RI Research Instruments Announces Major Orders for Enabling Technology for the Gamma-Ray Source of the Extreme Light Infrastructure (ELI) | 325 | RI Research Instruments, a company that is majority-owned by Bruker Corporation (Nasdaq: BRKR), today announced orders for key components and enabling subsystems for the research gamma ray source... ► Artikel lesen | ||
| 22.12.25 | MAFRA and KFPI: South Korean Government Honors Three Los Angeles Gems with 'Excellent Korean Restaurant' Designation | 221 | Seven global culinary landmarks in Los Angeles, Paris, and Singapore honored for excellence in taste, hygiene, and service.
Since 2022, the MAFRA and KFPI have vetted 23 elite establishments worldwide... ► Artikel lesen | ||
| 22.12.25 | Incyte Japan gibt die Zulassung von Zynyz (Retifanlimab) für die Erstlinienbehandlung von fortgeschrittenem Analkrebs bekannt | 253 | Incyte Biosciences Japan G.K. gab heute bekannt, dass das japanische Ministerium für Gesundheit, Arbeit und Soziales (MHLW) Zynyz (Retifanlimab) in Kombination mit Carboplatin und Paclitaxel (platinbasierte... ► Artikel lesen | ||
| 22.12.25 | Janus Henderson Group plc to be Acquired by Trian Fund Management and General Catalyst for $7.4 Billion | 431 | Janus Henderson Shareholders to Receive $49.00 per Share in Cash Transaction Represents a Premium of 18% to the Unaffected Closing Price on October 24, 2025 Significant Long-Term Investment... ► Artikel lesen | ||
| 22.12.25 | Huonslab Co., Ltd.: Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase 'HYDIZYME' | 236 | Applying HyDIFFUZE technology, aiming for Approval by MFDS in 2026 Huonslab, a subsidiary of Huons Global (KOSDAQ:084110), has submitted a Biologics License Application (BLA) to the Ministry... ► Artikel lesen | ||
| 22.12.25 | Anebulo Pharmaceuticals, Inc. Announces Its Intent to Commence a Self Tender Offer | 46 | AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic... ► Artikel lesen | ||
| 22.12.25 | Conduent Transportation: Conduent Launches Italy's First Integrated Transit EMV Contactless Payment System with Brescia Mobilità and Arriva Italia | 258 | Conduent advances innovation in public transportation with integrated EMV ticketing
Conduent Transportation, aglobal provider of smart mobility technology solutionsand business unit of Conduent... ► Artikel lesen | ||
| 22.12.25 | Jianshui Information Office: China Industry Leaders Convene in Jianshui to Chart the Blueberry Sector's Growth Path | 199 | The Third Yunnan Blueberry Conference and the release ceremony of the "Xinhua-Yunnan Honghe Blueberry Industry Development Index Report" opened on December 19 in Jianshui County, Honghe Hani and Yi... ► Artikel lesen | ||
| 22.12.25 | FusionLayer Expands Capabilities With Acquisition of Omnitele, Strengthening Its Position in Intelligent Mobile Networks | 227 | FusionLayer announced today the acquisition of Omnitele, a globally recognized expert in mobile network performance, analytics, and engineering. This acquisition greatly boosts FusionLayer's capabilities... ► Artikel lesen | ||
| 22.12.25 | Shape Memory Medical Inc.: Shape Memory Medical Secures EU MDR Certification for IMPEDE Embolization Plug Product Family, Accelerating Global Innovation in Vascular Care | 250 | Shape Memory Medical Inc., innovator of the proprietary shape memory polymer technology for endovascular applications, announced that its IMPEDE Embolization Plug product family has received certification... ► Artikel lesen | ||
| 22.12.25 | Otovo Acquires Soly Customers and Assets as it Expands Across Europe | 275 | Otovo acquires 24,000 customers and other assets from Soly for an approximately €0.75 million cash consideration
Otovo, a leading home energy service provider in the U.S. and Europe, today announced... ► Artikel lesen | ||
| 22.12.25 | Analystenbericht der GBC AG zu Mexedia S.p.A. Società Benefit abgeschlossen und veröffentlicht | 286 | Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) ("Mexedia" oder "Unternehmen") gibt bekannt, dass der von der GBC AG einem der führenden unabhängigen Finanzresearch-Unternehmen... ► Artikel lesen | ||
| 22.12.25 | Quanterix Corporation: Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence | 322 | Simoa p-Tau 217 Assay Enables Largest Population-Based Assessment (11,000+ Samples) Revealing Striking Age-Related Increase and Broad Treatment Eligibility
Quanterix Corporation(NASDAQ: QTRX),... ► Artikel lesen | ||
| 22.12.25 | Lithium Royalty Corp. Agrees to Be Acquired by Altius Minerals Corporation | 303 | TORONTO--(BUSINESS WIRE)--Lithium Royalty Corp. (the "Company" or "LRC") (TSX: LIRC) today announced that it has entered into a definitive arrangement agreement (the "Arrangement Agreement") with Altius... ► Artikel lesen | ||
| 22.12.25 | XCharge and EnBW Begin Expanded Testing of Fast-Charging Infrastructure | 495 | Eleven XCharge units deployed across four locations as part of EnBW's strategic testing program
HAMBURG, Germany--(BUSINESS WIRE)--XCharge is cooperating in testing with EnBW on their fast-charging-network... ► Artikel lesen | ||
| 22.12.25 | Newron Pharmaceuticals S.p.A.: Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week | 404 | Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral... ► Artikel lesen | ||
| 22.12.25 | Vertical Aerospace Doubles Flight Test Capacity With Final Prototype | 287 | Final prototype to expand flight test capacity and enable public demonstrations Initial all-electric testing ahead of hybrid-electric flights in 2026 Vertical progresses towards full... ► Artikel lesen | ||
| 22.12.25 | Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference | 213 | Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief... ► Artikel lesen | ||
| 22.12.25 | Kolibri Global Energy Inc. Provides Operations Update | 190 | Kolibri Global Energy Inc. (the "Company" or "Kolibri") (TSX: KEI, NASDAQ: KGEI) is pleased to provide an operations update on its latest wells in its Tishomingo field in Oklahoma.
FIELD UPDATE... ► Artikel lesen | ||
| 22.12.25 | Access Advance LLC: Hisense tritt dem HEVC Advance Patentpool bei | 308 | Access Advance LLC, weltweit führend im Bereich der Lizenzierung von Video-Codec-Patentpools, gab heute bekannt, dass Hisense Group Holdings Co., Ltd. dem HEVC Advance Patent Pool als Lizenznehmer... ► Artikel lesen | ||
| 22.12.25 | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Approval of EKTERLY (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema | 336 | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY (sebetralstat)... ► Artikel lesen | ||
| 22.12.25 | Havas Reports the Progress of Transactions Under Its Current Share Buyback Program | 312 | Regulatory News:
Havas N.V. (EURONEXT: HAVAS) hereby reports transaction details related to the €50 million buyback program as communicated on May 28, 2025.
From December 15, 2025, up to and... ► Artikel lesen | ||
| 22.12.25 | Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson's Disease | 212 | Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the... ► Artikel lesen | ||
| 22.12.25 | Zambon Biotech meldet erste Dosisverabreichung der klinischen Phase-3b-Studie ADIP zu IPX203 bei Parkinson | 250 | Zambon Biotech ein spezialisiertes Biotechnologie-Unternehmen der Zambon-Unternehmensgruppe, das den Aufbau eines wissenschaftlich fundierten und wirtschaftlich tragfähigen Portfolios innovativer... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .